Glaxo gets orders for H1N1 vaccine

GlaxoSmithKline said Friday several European governments had ordered stockpiles of a pandemic vaccine the British drugmaker is developing against the new H1N1 flu virus. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.